Company Overview and News

 
KLCI falls 0.34%, tracks regional losses

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): The FBM KLCI fell early on Monday, tracking the losses at key regional markets, dragged by index-linked blue chips.
5183 PECGF 5703 5168 9334 HRGHY

 
KLCI rises 0.77% as banks, select blue chips lift

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI rose 0.77% in early trade, lifted by index-linked banking stocks as well other select blue chips.
HLFBF PNADF PBLOF 5183 PECGF 5703 5819 1082 5681 1295 PNAGF 6033

 
Muhibbah Engineering 2Q net profit down 12.8% on lower revenue

2018-08-30 theedgemarkets
KUALA LUMPUR (Aug 30): Muhibbah Engineering (M) Bhd’s second quarter net profit slipped 12.78% to RM33.0 million, from RM37.83 million a year earlier, due to a lower revenue.
5703

 
Small-cap stocks offer investors stronger growth prospects, says CIMB Research

2018-07-25 theedgemarkets
KUALA LUMPUR (July 25): Small capitalised (small caps) stocks have the potential to generate returns the long run despite having underperformed so far this year, according to CIMB Research.
7216 5703 4405 7246 8079 7035

 
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-07-03 theedgemarkets
THE ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

14
The Week Ahead: Awaiting Cabinet line-up and new Umno president

2018-06-25 theedgemarkets
The ringgit, which last week breached the psychological RM4 mark against the US dollar for the first time in five months, is in the spotlight again. At the time of writing last Friday (June 22), the ringgit fetched 4.0022 against the greenback. The ringgit’s fair value should be 3.80, Prime Minister Tun Dr Mahathir Mohamad told Bloomberg in a June 22 interview. “We would like to strengthen our ringgit, but it should be done naturally,” he said.
SARKF MLYNF 8664 6521 7237 1171 5158 8583 0012 4898 3883 5126 7229 SMEBF 5703 MYTEF MLYBY 4197 5202 7164 5222 1155 4588 4863 3158 4723

58
Consolidation of the oil and gas sector not fast enough

2018-06-12 thestar.com.my
The steady recovery in crude oil prices over the past one year has yet to have a big positive impact on OGSE players. This is partly because oil majors have yet to increase their capex in a big way.
RDS.B RDS.A XOM RDSB RDSA 8133 5255 9466 BHI 7206 5703 RYDBF RYDAF BSMAF 1818

1
Possible headwinds from mega project review

2018-05-10 thestar.com.my
PETALING JAYA: The new ruling coalition Pakatan Harapan’s (PH) move to review some mega projects may create some headwinds in the construction sector in the short term, but as clarity prevails, it could benefit the sector on the whole and ease expected selling pressure on construction stocks.
5703 5263

1
YTL Corp pulls off surprise

2018-04-07 thestar.com.my
YTL Corp Bhd has again caught the market by surprise with its recent win of a portion of the job in the multi-billion ringgit Kuala Lumpur–Singapore High Speed Rail (HSR) project.
3204 5226 5703 9679

2
Trading ideas: Scientex, Advancecon, Bina Puri, Titijaya, Muhibbah

2018-03-23 thestar.com.my
KUALA LUMPUR: Scientex Bhd , Advancecon Holdings Bhd, Bina Puri Holdings Bhd , Titijaya Land Bhd and Muhibbah Engineering (M) Bhd are among the stocks to watch on Friday, according to JF Apex Research.
5239 5932 5703 2593

 
Gamuda-MMC-George Kent JV likely to win MRT3 contract

2018-03-21 thestar.com.my
Smooth ride: A file picture showing an MRT train moving towards Kajang from Kuala Lumpur. MRT3’s proposed alignment will see it integrated with MRT1, MRT2 and other major urban rail transport systems.
3204 5703

 
Muhibbah shares up 6% on contract win

2018-03-12 thestar.com.my
KUALA LUMPUR: Muhibbah Engineering (M) Bhd ’s shares got a boost in morning trade after the group clinched a RM57.6mil contract from Prasarana Malaysia Bhd.
5703

 
Trading ideas: UMW, Keck Seng, Muhibbah, Heitech Padu, Sasbadi

2018-03-12 thestar.com.my
KUALA LUMPUR: UMW Holdings Bhd , Keck Seng (M) Bhd , Muhibbah Engineering (M) Bhd , Heitech Padu Bhd and Sasbadi Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.
3476 5028 4588 5703 5252 5983

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...